Physician profile
Eric D Libby
NPI 1922048016
$1,771.32
in general payments reported to CMS, 2019-2025
20 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $204 · 2021: $71.26 · 2024: $307 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.81 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.04 | 2019-2025 | |
| Pfizer INC. | $287.67 | 2019-2024 | |
| Genzyme Corporation | $186.14 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.66 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $123.39 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $75.85 | 2019-2025 | |
| Shire North American Group INC | $49.74 | 2019 | |
| Shionogi INC | $44.99 | 2019 | |
| Allergan, INC. | $40.57 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $39.28 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $35.97 | 2019 | |
| Celgene Corporation | $35.95 | 2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $32.27 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $28.63 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $26.75 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $25.58 | 2019-2020 | |
| Janssen Biotech, INC. | $21.85 | 2019 | |
| Merck Sharp & Dohme LLC | $19.40 | 2021 | |
| Intercept Pharmaceuticals, INC. | $19.33 | 2019 | |
| Ucb, INC. | $18.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Libby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.